英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
ranks查看　ranks　在百度字典中的解释百度英翻中〔查看〕
ranks查看　ranks　在Google字典中的解释Google英翻中〔查看〕
ranks查看　ranks　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Nuvation Bio Inc. - U. S. Food and Drug Administration . . .
    IBTROZI is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor therapy approved for the treatment of adult patients with advanced ROS1-positive non-small cell lung cancer
  • FDA approves taletrectinib for ROS1-positive non-small cell . . .
    On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc ), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small
  • Ibtrozi for Non-Small-Cell Lung Cancer - WebMD
    Ibtrozi is a medicine called a kinase inhibitor that is used to treat a certain type of lung cancer called non-small-cell lung cancer (NSCLC) that is caused by an abnormal ROS1 gene
  • FDA Approves Ibtrozi for ROS1+ Advanced Non-Small Cell Lung . . .
    For patients with ROS1-positive non-small cell lung cancer who had not previously received a tyrosine kinase inhibitor, Ibtrozi was associated with a high rate of disease control—meaning the cancer either shrank or stopped growing — in 95% of response-evaluable patients Most people responded within about six weeks
  • Ibtrozi™ (Taletrectinib) | A New Era in ROS1-Positive NSCLC . . .
    Explore Ibtrozi (taletrectinib), the newly FDA-approved ROS1-targeted therapy for non-small cell lung cancer Discover its mechanism, trial data, clinical use, and market impact
  • Nuvation Bio and Eisai Apply for Lung Cancer Drug Approval
    Application Accepted: The European Medicines Agency has accepted the Marketing Authorisation Application for taletrectinib filed by Nuvation Bio and Eisai, targeting non-small cell lung cancer, marking a significant advancement in the companies' oncology portfolio Review Timeline: The application is assigned a standard review period of 210 'active' days, which will influence the drug's time
  • FDA Approves Nuvation Bio’s Ibtrozi for Locally Advanced or . . .
    FDA Approves Ibtrozi for ROS1+ NSCLC: Ibtrozi (taletrectinib) has been approved for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), based on strong results from the TRUST-I and TRUST-II trials
  • US FDA approves Nuvation Bios rare lung cancer drug
    The FDA has granted approval for Nuvation Bio's Ibtrozi, a novel oral drug designed to treat ROS1-positive non-small cell lung cancer, providing hope for thousands of patients annually
  • Taletrectinib (Ibtrozi): What Patients Should Know About in . . .
    It is non-interventional, meaning Taletrectinib is given as part of standard medical care, and researchers are collecting data on how patients respond, how long the treatment works, and what side effects occur Taletrectinib (Ibtrozi) represents an exciting advancement for patients with ROS1-positive non-small cell lung cancer
  • Eisai, Nuvation Bio Application Seeking Approval of Ibtrozi . . .
    Premium NEW YORK – Eisai and Nuvation Bio said on Thursday that the European Medicines Agency (EMA) has accepted its marketing authorization application (MAA) for Ibtrozi (taletrectinib) for treating advanced ROS1-positive non-small cell lung cancer





中文字典-英文字典  2005-2009